Health Care • Biotechnology: Pharmaceutical Preparations
$1.56 ▼ -0.10
(-6.02%)
MKT CAP: $118.9M • VOL: 1.21M
52W L $1 52W H $4
NKTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$122.0M | -$128.2M | -$131.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$104.1M | -$108.8M | -$117.5M |
| EBITDA (Normalized) | -$121.0M | -$124.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$88.7M | -$99.7M | -$86.2M |
| Capital Expenditures (CapEx) | $1.2M | $4.4M | — |
| Free Cash Flow (FCF) | -$89.9M | -$104.1M | -$86.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -35.3% | -26.6% | — |
| Cash & Short-Term Equivalents | $39.6M | $27.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $312.3M | $408.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NKTX.